证券代码：301290 证券简称：东星医疗 公告编号：2025-018 江苏东星智慧医疗科技股份有限公司 关于与专业投资机构共同投资相关事项暨关联交易的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、与专业投资机构共同投资相关事项暨关联交易的概述 江苏东星智慧医疗科技股份有限公司（以下简称"公司"）于 2024 年 8 月 23 日召开第四届董事会第三次会议、第四届监事会第三次会议，审议通过了《关 于与专业投资机构共同投资暨关联交易的议案》，为促进公司长远发展，充分借 助专业投资机构的资源优势，更好地完成产业布局、以提升综合竞争力，在不影 响公司日常经营和发展、有效控制投资风险的前提下，公司与北京朗姿韩亚资产 管理有限公司、常州国星投资管理有限公司、常州钟楼科创投资合伙企业（有限 合伙）、常州信辉创业投资有限公司、北海丰灏创业投资有限公司共同出资设立 常州朗亚国星医疗投资合伙企业（有限合伙）（以下简称"合伙企业"或"基金"）， 全体合伙人的认缴出资额为人民币 10,000 万元，公司作为有限合伙人以自有资 金认缴出资 2,500 万元，占出资总额 ...

一、主要会计数据和财务指标 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 2213.45万股，累计占流通股比： 32.48%，较上期变化：0.00 。 | 名称 | 持有数量(万股) | 占总股本 | 增减情 | | --- | --- | --- | --- | | | | 比例(%) | 况(万股) | | 江世华 | 507.00 | 7.44 | 不变 | | 王海龙 | 431.00 | 6.32 | 不变 | | 苏州济峰股权投资合伙企业(有限合伙) | 403.49 | 5.92 | 不变 | | 常州中鼎天盛创业投资合伙企业(有限合伙) | 202.24 | 2.97 | 不变 | | 南京凯腾瑞杰创业投资企业(有限合伙) | 150.00 | 2.20 | 不变 | | 海南平安私募基金管理有限公司-平安阖鼎新三板投资精英之联 创一期基金 | 138.89 | 2.04 | 不变 | | 华泰证券（601688）资管-兴业银行（601166）-华泰东星医疗 | | | | | （301290）家园1号创业板员工持股集合资产管理计划 | 113.40 | 1.66 | 不变 | ...

Financial Performance - The company's revenue for Q1 2025 was ¥78,186,465.07, a decrease of 14.84% compared to ¥91,814,686.88 in the same period last year[5] - Net profit attributable to shareholders was ¥12,063,975.22, down 39.35% from ¥19,890,650.72 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥6,267,512.03, reflecting a decline of 49.10% compared to ¥12,313,887.76 in the previous year[5] - Basic and diluted earnings per share decreased by 40.00% to ¥0.12 from ¥0.20 year-on-year[5] - Net profit for the current period is 11,673,597.10, a decrease of 40.4% compared to 19,593,040.69 in the previous period[24] - Operating profit for the current period is 14,300,919.19, down from 23,846,785.88, reflecting a decline of 40.2%[24] - Total comprehensive income for the current period is 11,673,597.10, compared to 19,593,040.69 in the previous period[25] Cash Flow - The net cash flow from operating activities was negative at -¥8,644,285.96, a significant drop of 136.52% from ¥23,671,274.75 in the same period last year[5] - Cash flow from operating activities shows a net outflow of -8,644,285.96, compared to a net inflow of 23,671,274.75 in the previous period[27] - Cash flow from investment activities results in a net outflow of -50,149,819.47, an improvement from -326,688,357.82 in the previous period[28] - The company reported a decrease in cash inflow from operating activities, totaling 97,064,672.74, down from 114,753,819.18[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,480,830,664.33, a slight decrease of 0.06% from ¥2,482,438,025.25 at the end of the previous year[5] - Total current assets increased slightly to ¥1,427,814,741.49 from ¥1,423,545,701.77, a growth of 0.2%[20] - Total liabilities decreased to ¥215,599,582.22 from ¥228,880,540.24, a reduction of 5.8%[21] - The company reported a financial expense of ¥242,468.51, compared to a financial income of -¥1,724,609.95 in the previous period[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,853, with no preferred shareholders[13] - The largest shareholder, Wan Shiping, holds 25.02% of the shares, totaling 25,063,734 shares[13] - The company has no preferred shareholders and no changes in the number of restricted shares during the reporting period[15] Operating Costs and Expenses - Total operating revenue for the current period was ¥78,186,465.07, a decrease of 14.9% compared to ¥91,814,686.88 in the previous period[23] - Total operating costs decreased to ¥72,372,834.27 from ¥78,189,414.84, reflecting a reduction of 7.3%[23] - Operating costs included ¥43,469,650.62 in cost of goods sold, down from ¥48,552,852.60, indicating a decrease of 10.5%[23] - Research and development expenses were ¥4,169,622.11, a decrease of 13.2% from ¥4,804,803.02 in the previous period[23] Cash and Cash Equivalents - The company reported a significant decrease in cash and cash equivalents, down 68.56% to ¥92,804,243.60 from ¥295,179,331.27[9] - Cash and cash equivalents at the end of the period were ¥92,804,243.60, down from ¥295,179,331.27, a decline of 68.6%[19] - Cash and cash equivalents at the end of the period stand at 90,402,668.60, down from 237,281,126.32[28] Financial Expenses and Income - Financial expenses increased by 114.06% to ¥242,468.51 due to higher bank loan interest payments[10] - Other income decreased by 66.04% to ¥904,710.09, primarily due to a reduction in government subsidies received[10] - Total revenue from interest income is 115,402.24, while other income amounts to 904,710.09, contributing to a total of 1,020,112.33[24] Dividend and Interest Payments - Cash paid for dividends and interest surged by 1,313.46%, from ¥18,105.56 to ¥255,914.89, driven by increased interest and discount expenses[11] - Cash paid for debt repayment increased by 1,092.16%, from ¥100,000.00 to ¥1,192,155.00, primarily due to higher bank loan repayments[11] - Cash received from borrowings surged by 11,209.46%, from ¥291,723.44 to ¥32,992,344.35, reflecting an increase in bank loans during the reporting period[11]

证券代码：301290 证券简称：东星医疗 公告编号：2025-016 江苏东星智慧医疗科技股份有限公司 关于2025年第一季度报告披露的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 为使投资者全面了解公司2025年第一季度的经营成果及财务状况，公司《 2025年第一季度报告》全文于2025年4月25日在中国证券监督管理委员会指定 的创业板信息披露网站巨潮资讯网(www.cninfo.com.cn)上进行披露。 敬请广大投资者注意查阅。 特此公告。 江苏东星智慧医疗科技股份有限公司 董事会 2025年4月25日 江苏东星智慧医疗科技股份有限公司(以下简称"公司")于2025年4月24日 召开第四届董事会第九次会议和第四届监事会第八次会议，审议通过了《关于公 司<2025年第一季度报告>全文的议案》。 ...

华泰联合证券有限责任公司（以下简称"华泰联合证券"、"保荐人"）作为 江苏东星智慧医疗科技股份有限公司（以下简称"东星医疗"、"公司"）首次公 开发行股票并创业板上市的保荐人，根据《深圳证券交易所上市公司自律监管指 引第 13 号——保荐业务》《深圳证券交易所创业板股票上市规则》和《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等法规和规 则的相关规定以及东星医疗的实际情况，认真履行保荐人应尽的职责，对东星医 疗的董事、监事、高级管理人员等相关人员进行了有计划、多层次的后续培训， 所培训的内容严格按照中国证券监督管理委员会及深圳证券交易所创业板有关 持续督导的最新要求进行。 2025 年 4 月 14 日，华泰联合证券相关人员按照《深圳证券交易所上市公司 自律监管指引第 13 号——保荐业务》的要求完成了对东星医疗董事、监事、高 级管理人员等相关人员的持续培训工作，特向贵所报送培训工作报告。 一、培训的主要内容 华泰联合证券有限责任公司 关于江苏东星智慧医疗科技股份有限公司持续督导期 2024年培训情况报告 深圳证券交易所： 根据《深圳证券交易所上市公司自律监管指引第 13 号—— ...

华泰联合证券有限责任公司 关于江苏东星智慧医疗科技股份有限公司 2024 年度跟踪报告 | 保荐人名称：华泰联合证券有限责任公司 | 被保荐公司简称：东星医疗 | | --- | --- | | 保荐代表人姓名：庄晨 | 联系电话：025-83388070 | | 保荐代表人姓名：黄飞 | 联系电话：025-83388070 | | 事项 | 存在的问题 | 采取的措施 | | --- | --- | --- | | 1.信息披露 | 无 | 不适用 | | 2.公司内部制度的建立和执行 | 无 | 不适用 | | 3．"三会"运作 | 无 | 不适用 | | 4.控股股东及实际控制人变动 | 无 | 不适用 | | 5.募集资金存放及使用 | 无 | 不适用 | | 6.关联交易 | 无 | 不适用 | | 7.对外担保 | 无 | 不适用 | | 8.购买、出售资产 | 无 | 不适用 | | 9.其他业务类别重要事项（包 | | | | 括对外投资、风险投资、委托 | 无 | 不适用 | | 理财、财务资助、套期保值 | | | | 等） | | | | 10．发行人或者其聘请的证券 | 无 | 不适用 ...

Policy Developments - The National Medical Products Administration (NMPA) approved the registration of 308 medical device products as of March 2025, including 248 domestic Class III medical devices, 34 imported Class III medical devices, 19 imported Class II medical devices, and 7 medical devices from Hong Kong, Macau, and Taiwan [1] Drug Approvals - Chengdu Saijing Bio's ursodeoxycholic acid oral suspension has been approved as the first domestic generic Class 3.1 new drug for treating cystic fibrosis-associated liver disease (CFALD), filling a gap in the market for this indication [2] - Kowa Company's pemafibrate tablets have been approved in China for the treatment of dyslipidemia [3] - Merck Sharp & Dohme (MSD) announced that its nine-valent HPV vaccine has received approval for male use in China, targeting males aged 16-26, enhancing public awareness of HPV infections in men [5] Capital Market - Zhongjie Chaorun completed a Pre-A round financing of several million yuan, primarily for clinical trials of its artificial meniscus implant and commercialization of its innovative meniscus suturing device [4] Financial Reports - Aoyang Health reported a 2024 revenue of 2.01 billion yuan, a year-on-year decrease of 7.54%, with a net profit of 40.56 million yuan, down 18.36% [6] - Novogene announced a total revenue of 2.111 billion yuan for 2024, a year-on-year increase of 5.45%, with a net profit of 197 million yuan, up 10.52% [7] - Tianyi Medical reported a revenue of 419 million yuan for 2024, a year-on-year increase of 9.98%, but a net loss of 744,000 yuan [8] - Luoxin Pharmaceutical disclosed a net loss of 962 million yuan for 2024, despite a revenue increase of 11.99% to 2.647 billion yuan [9] - Dongxing Medical reported a revenue of approximately 435 million yuan for 2024, a slight increase of 0.4%, with a net profit of about 97.42 million yuan, up 0.21% [10] Public Sentiment - Xinbang Pharmaceutical announced the resignation of independent director Zhou Jun, with the company reporting a revenue of 6.032 billion yuan for 2024, down 6.63%, and a net profit of 101 million yuan, down 64.70% [11] - Shuangcheng Pharmaceutical warned of potential delisting risk due to expected negative net profit and revenue below 300 million yuan for 2024 [12]

Group 1 - Company Instech reported a net profit of 177 million yuan for 2024, a year-on-year increase of 28.15%, with a proposed cash dividend of 1.20 yuan per 10 shares [1] - Instech achieved an operating revenue of 1.185 billion yuan in 2024, representing a year-on-year growth of 24.45% [1] - The company specializes in the research, production, and sales of rare earth permanent magnet materials and applications [2] Group 2 - Company Junda reported a net loss of 106 million yuan for Q1 2025, transitioning from profit to loss, with a year-on-year revenue decline of 49.52% [3] - Junda's operating revenue for Q1 2025 was 1.875 billion yuan [3] - The company focuses on the research, production, and sales of photovoltaic cell products [4] Group 3 - Company Annada reported a net loss of 10.26 million yuan for Q1 2025, with a year-on-year revenue increase of 1.44% [5] - Annada's operating revenue for Q1 2025 was 473 million yuan [5] - The company specializes in titanium dioxide and iron phosphate products [6] Group 4 - Company Jiuzhou Pharmaceutical reported a net profit of 250 million yuan for Q1 2025, a year-on-year increase of 5.68% [7] - Jiuzhou's operating revenue for Q1 2025 was 1.49 billion yuan, reflecting a year-on-year growth of 0.98% [7] - The company provides custom research and production services for pharmaceutical companies and research institutions [8] Group 5 - Company Yitong Century won a 1.48 billion yuan contract for a 5G comprehensive maintenance project with Guangdong Unicom [9] - The project will enhance the company's business volume and expansion in Guangdong [9] - Yitong Century specializes in communication network technology services and solutions [10] Group 6 - Company Rijiu Optoelectronics reported a net profit of 67.47 million yuan for 2024, a year-on-year increase of 506.9%, with a proposed cash dividend of 2.00 yuan per 10 shares [10] - Rijiu's operating revenue for 2024 was 583 million yuan, representing a year-on-year growth of 22% [10] - The company focuses on the research, production, and sales of touch display application materials [11] Group 7 - Company Ruotong reported a net profit of 95.98 million yuan for 2024, a year-on-year increase of 0.91%, with a proposed cash dividend of 2.00 yuan per 10 shares [12] - Ruotong's operating revenue for 2024 was 408 million yuan, reflecting a year-on-year growth of 7.54% [12] - The company specializes in drilling and completion equipment for oil and gas [13] Group 8 - Company Shuangxiang reported a net profit of 472 million yuan for 2024, a year-on-year increase of 754.84%, with a proposed cash dividend of 1.50 yuan per 10 shares [14] - Shuangxiang's operating revenue for 2024 was 2.29 billion yuan, representing a year-on-year growth of 51.55% [14] - The company focuses on synthetic leather and optical-grade PMMA products [15] Group 9 - Company Xinfang Pharmaceutical reported a net profit of 101 million yuan for 2024, a year-on-year decrease of 64.70%, with a proposed cash dividend of 0.30 yuan per 10 shares [16] - Xinfang's operating revenue for 2024 was 6.032 billion yuan, reflecting a year-on-year decline of 6.63% [16] - The company is involved in medical services, pharmaceutical distribution, and manufacturing [17] Group 10 - Company Dongxing Medical reported a net profit of 97.42 million yuan for 2024, a year-on-year increase of 0.21%, with a proposed cash dividend of 6.00 yuan per 10 shares [18] - Dongxing's operating revenue for 2024 was 435 million yuan, reflecting a year-on-year growth of 0.40% [18] - The company specializes in surgical medical devices [19] Group 11 - Company Wuzhou Special Paper reported a net profit of 64.68 million yuan for Q1 2025, a year-on-year decrease of 51.56%, with an operating revenue of 1.989 billion yuan [20] - Wuzhou's operating revenue for Q1 2025 increased by 15.21% [20] - The company focuses on the research, production, and sales of mechanism paper and pulp [21] Group 12 - Company Jinrui Mining expects a net profit of 15.28 million yuan for Q1 2025, a year-on-year increase of 617.40% [22] - The company specializes in the production and sales of strontium salt products [23] Group 13 - Company Youyan New Materials expects a net profit of 60 million to 75 million yuan for Q1 2025, a year-on-year increase of 13076% to 16370% [24] - The company focuses on electronic films, precious metal materials, and rare earth materials [25] Group 14 - Company Guoli expects a net profit of 11 million to 13 million yuan for Q1 2025, a year-on-year increase of 164.38% to 212.45% [26] - The company specializes in urban infrastructure design, construction, and investment [27] Group 15 - Company Shenzhen Airport reported a passenger throughput of 5.5422 million in March, a year-on-year increase of 8.70% [28] - The airport's cargo throughput was 171,900 tons, reflecting a year-on-year growth of 14.51% [28] - The company is involved in aviation and related non-aviation businesses [29] Group 16 - Company Shenghui Integration reported an order balance of 2.117 billion yuan as of March 31, 2025, a year-on-year increase of 11.89% [30] - The company provides cleanroom engineering and electromechanical engineering services [31] Group 17 - Company Chengyi Pharmaceutical received a drug registration certificate for Mercaptopurine tablets [32] - The drug is applicable for various diseases including choriocarcinoma and acute lymphoblastic leukemia [32] Group 18 - Company Enhua Pharmaceutical initiated Phase I clinical trials for NH280105 capsules, targeting Alzheimer's disease [33] - The trial aims to assess the safety and pharmacokinetics of the drug [33] Group 19 - Company Lingang Steel proposed a share buyback of 50 million to 100 million yuan [34] - The company specializes in the production and development of metallurgical products [35] Group 20 - Company Fujia plans to repurchase shares worth 15 million to 30 million yuan [36] - The company focuses on smart cleaning appliances and key components [37] Group 21 - Company Mould Technology received a project designation letter for exterior parts from a luxury car client, with an estimated total sales of 2.07 billion yuan [38] - The project is expected to start mass production in April 2027 [38] Group 22 - Company Longxin General expects a net profit of 4.55 billion to 5.30 billion yuan for Q1 2025, a year-on-year increase of 76.65% to 105.77% [39] - The company specializes in motorcycles, engines, and general machinery products [40] Group 23 - Company Dongfang Securities reported a net profit of 1.436 billion yuan for Q1 2025, a year-on-year increase of 62.08% [41] - The company focuses on investment management and securities trading [42] Group 24 - Company Yalian Machinery plans to use up to 800 million yuan of idle funds for low-risk financial products [43] - The company specializes in the production of engineered wood production lines and equipment [44] Group 25 - Company Guanghua Technology reported a net loss of 205 million yuan for 2024, with total revenue of 2.589 billion yuan [45] - The company focuses on PCB chemicals and lithium battery materials [46] Group 26 - Company Boya Biotechnology plans to publicly transfer 80% of its subsidiary's equity for 213 million yuan [47] - The transaction aims to optimize resource allocation focusing on blood products [48] Group 27 - Company Darui Electronics plans to repurchase shares worth 30 million to 50 million yuan [49] - The company specializes in customized components and automation equipment [50] Group 28 - Company Hongying Intelligent plans to repurchase shares worth 30 million to 40 million yuan [51] - The company focuses on smart control products and assemblies [52] Group 29 - Company Guangku Technology announced a change in the upper shareholding structure of its controlling shareholder [53] - The operational activities of the company will not be materially affected [54] Group 30 - Company Dingjie Smart's application for convertible bond issuance has been accepted by the Shenzhen Stock Exchange [55] - The company provides digital and intelligent solutions for various industries [56]

二○二四年度 内部控制审计报告 信会师报字[2025]第 ZA10886 号 江苏东星智慧医疗科技股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了江苏东星智慧医疗科技股份有限公司（以下简称 东星医疗）2024 年 12 月 31 日的财务报告内部控制的有效性。 江苏东星智慧医疗科技股份有限公司 内部控制审计报告 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 内控审计报告 第 1 页 四、 财务报告内部控制审计意见 我们认为，东星医疗于 2024 年 12 月 31 日按照《企业内部控制 基本规范》和相关规定在所有重大方面保持了有效的财务报告内部控 制。 立信会计师事务所 中国注册会计师： 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是东星医疗董事会的责任。 二 ...

江苏东星智慧医疗科技股份有限公司 审计报告及财务报表 二○二四年度 江苏东星智慧医疗科技股份有限公司 审计报告及财务报表 （2024 年 01 月 01 日至 2024 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-5 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-97 | 审计报告 信会师报字[2025]第 ZA10883 号 江苏东星智慧医疗科技股份有限公司全体股东： 一、 审计意见 我们审计了江苏东星智慧医疗科技股份有限公司（以下简称东星 医疗）财务报表，包括 2024 年 12 月 31 日的合并及母公司资产负债 表，2024 年度的合并及母公司利润表、合并及母公司现金流量表、 合并及母公司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面 ...